Entity

Time filter

Source Type


Baranov A.A.,Moscow State University | Ivanov D.O.,North State Medical University | Alyamovskaya G.A.,Russian National Research Medical University | Amirova V.R.,Bashkir State Medical University | And 34 more authors.
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk | Year: 2014

In 2010, the Russian Federation (RF) registered palivizumab - innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease. Currently, palivizumab is included in the list of recommended medicines and medical care standards of different countries, including Russia. In the review the results of Russian research on the progress of RSV infection, its epidemiology and immunization experience gained over the 2010-2014 period are summarized in relation to the foreign data. During the four epidemic seasons palivizumab immunization covered more than 3,200 children of severe RSV infection risk group with a progressive annual increase in the number of patients who received the drug. Geography of palivizumab immunization is also greatly expanded in our country during this time. If during the first two seasons measures of immunization were taken mainly in Moscow and St. Petersburg, at the present time, thirty one territorial entities of the Russian Federation have the experience in the drug application. Analysis of the results of RSV infection immunization (made in several regions) confirms the high clinical efficacy and palivizumab safety already demonstrated in international studies. In addition, the analysis presents the potential to improve the efficiency of the integrated RSV infection immunization programs, realizing in the establishment of high-risk child group register, adequate counseling for parents, as well as the development of the routing of patients and coordination of interaction between different health institutions during the immunization. © 2014, Izdatel'stvo Meditsina. All rights reserved. Source


Drui A.E.,Ural Federal University | Shorikov E.V.,RAS Institute of High Temperature Electrochemistry | Tsaur G.A.,RAS Institute of High Temperature Electrochemistry | Popov A.M.,RAS Institute of High Temperature Electrochemistry | And 4 more authors.
Voprosy Onkologii | Year: 2014

Bone marrow (BM) involvement in neuroblastoma patients is commonly detected by cytomorphology and associated with poor outcome. Molecular techniques, flow cytometry and immunocytochemistry were offered to detect low number of tumor cells in BM due to high value of analytical sensitivity, while prognostic significance of results, obtained with these methods is unclear. PHOX2B and/or TH genes expression was selected as molecular marker of BM involvement. It was determined in 411 BM samples obtained from 75 neuroblastoma patients. 263 BM samples were taken at the time of primary diagnosis, 80 during treatment and 68 before autologous stem cells (ASC) apheresis. Prognostic significance of BM involvement was defined using 5-year (in some groups 4-year) overall (OS), event free (EFS) and progression free (PFS) survival. 24 patients (32.0%) were positive for PHOX2B and/or TH expression in the BM at the time of primary diagnosis. They had decreased survival rates: EFS achieved 0.49±0.12, OS - 0.57±0.12, PFS - 0.54±0.12, comparing with 0.75±0.07, 0.80±0.07 and 0.77±0.07, respectively, in patients with negative BM, p=0.014, p=0.029 and p=0.033. The trend to decreased OS and PFS was detected in case of minimal residual disease presence at the end of the induction chemotherapy (OS and PFS both are 0.22±0.19 vs. 0.70±0.18 and 0.43±0.22, correspondingly, p=0.121, p=0.130). Detection of PHOX2B and/or TH genes expression in the BM before ASC harvesting led to significant decreasing of EFS and OS (0.00 vs. 0.59±0.14 and 0.75±0.13, respectively, p=0.021 and p=0.016). Source


Semeshina O.V.,Regional Childrens Clinical Hospital No. 1 | Luchaninova V.N.,Vladivostok State Medical University | Kovalchuk V.K.,Vladivostok State Medical University | Melnikova E.A.,Regional Childrens Clinical Hospital No. 1
Human Ecology | Year: 2014

Influence of anthropo-man-induced load on Dysmetabolic Nephropathy (DMN) and Urolithiasis (U) prevalence in children of the Primorsky Krai has been studied. The study design included a sanitary, epidemiological and clinical stages. 513 children aged 3-14 years, born and residing in three towns of the Primorsky Krai with different degrees of anthropo-man-induced load stress have been examined (in Vladivostok, Dalnegorsk and Partizansk). The highest anthropo-man-induced water and air pollution load level was observed in Vladivostok. In the City of Dalnegorsk, water and air were less polluted, but the level of soil contamination (4.0 versus 1.0 and 2.0 in Vladivostok and Partizansk) was the highest one. DMN and U occurred significantly more frequently in Dalnegorsk than in Vladivostok and Partizansk (? < 0.001). It has been proved that in the Primorsky Krai, the anthropo-man-induced factor was not a priority risk factor for DMN and U development. Use of the noninvasive and easily managed system "Litos-test" allowed to reliably detect these diseases in the examined children. Source


Drui A.E.,RAS Institute of High Temperature Electrochemistry | Tasaur G.A.,RAS Institute of High Temperature Electrochemistry | Shorikov E.V.,RAS Institute of High Temperature Electrochemistry | Popov A.M.,RAS Institute of High Temperature Electrochemistry | And 5 more authors.
Voprosy Onkologii | Year: 2013

MYCN gene amplification and 1p deletion in neuroblastoma patients are associated with poor prognosis and commonly used for patient's stratification into risk groups. MYCN copy number and 1p deletion status were analyzed with multiplex ligase-dependent probe amplification (MLPA), PCR and FISH. MYCN amplification was revealed in 21 patients (17.2%) simultaneously by MLPA and PCR. In 28 cases (23.0%) 2p gain was detected. 1p deletion was revealed in 28 patients (23.0%) while concordance between PCR and MLPA achieved 95.8%, PCR and FISH - 90.9%. Mean follow-up time achieved 42 months (ranged from 1 month to 13 years). Event-free survival and overall survival in MYCN-amplified patients as well as in patients with 1p deletion were significantly lower comparing with MYCN-negative patients or patients without 1p deletion. Source

Discover hidden collaborations